You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
A first-in-human phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody navicixizumab (OMP-305B83) in patients with previously treated solid tumors
|
|---|---|
| Published in |
Investigational New Drugs, September 2018
|
| DOI | 10.1007/s10637-018-0665-y |
| Pubmed ID | |
| Authors |
Antonio Jimeno, Kathleen N. Moore, Michael Gordon, Rashmi Chugh, Jennifer R. Diamond, Raid Aljumaily, David Mendelson, Ann M. Kapoun, Lu Xu, Robert Stagg, David C. Smith |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 65 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 65 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 10 | 15% |
| Student > Master | 6 | 9% |
| Researcher | 5 | 8% |
| Other | 5 | 8% |
| Student > Doctoral Student | 4 | 6% |
| Other | 8 | 12% |
| Unknown | 27 | 42% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 12 | 18% |
| Immunology and Microbiology | 6 | 9% |
| Agricultural and Biological Sciences | 5 | 8% |
| Biochemistry, Genetics and Molecular Biology | 4 | 6% |
| Nursing and Health Professions | 2 | 3% |
| Other | 7 | 11% |
| Unknown | 29 | 45% |
Attention Score in Context
This research output has an Altmetric Attention Score of 56. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 May 2022.
All research outputs
#772,322
of 25,743,152 outputs
Outputs from Investigational New Drugs
#12
of 1,266 outputs
Outputs of similar age
#16,327
of 352,656 outputs
Outputs of similar age from Investigational New Drugs
#1
of 22 outputs
Altmetric has tracked 25,743,152 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,266 research outputs from this source. They receive a mean Attention Score of 5.0. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 352,656 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 22 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 95% of its contemporaries.